vs
Side-by-side financial comparison of Farmland Partners Inc. (FPI) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
Farmland Partners Inc. is the larger business by last-quarter revenue ($20.7M vs $19.1M, roughly 1.1× NewAmsterdam Pharma Co N.V.). Farmland Partners Inc. runs the higher net margin — 103.4% vs -90.7%, a 194.1% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -3.5%).
Farmland Industries was the largest agricultural cooperative in North America when it eventually sold all of its assets in 2002–04. During its 74-year history, Farmland served its farmer membership as a diversified, integrated organization, playing a significant role in agricultural markets both domestically and worldwide.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
FPI vs NAMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.7M | $19.1M |
| Net Profit | $21.4M | $-17.4M |
| Gross Margin | — | — |
| Operating Margin | — | -186.1% |
| Net Margin | 103.4% | -90.7% |
| Revenue YoY | -3.5% | 740.1% |
| Net Profit YoY | -63.5% | 55.5% |
| EPS (diluted) | $0.44 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.7M | — | ||
| Q3 25 | $11.3M | — | ||
| Q2 25 | $10.0M | $19.1M | ||
| Q1 25 | $10.3M | — | ||
| Q4 24 | $21.5M | $12.8M | ||
| Q3 24 | $13.3M | $29.1M | ||
| Q2 24 | $11.4M | — | ||
| Q1 24 | $12.0M | — |
| Q4 25 | $21.4M | — | ||
| Q3 25 | $483.0K | — | ||
| Q2 25 | $7.6M | $-17.4M | ||
| Q1 25 | $2.0M | — | ||
| Q4 24 | $58.7M | $-92.2M | ||
| Q3 24 | $1.8M | $-16.6M | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 78.2% | -186.1% | ||
| Q1 25 | 20.6% | — | ||
| Q4 24 | — | -338.5% | ||
| Q3 24 | 13.9% | -85.9% | ||
| Q2 24 | -17.9% | — | ||
| Q1 24 | 11.9% | — |
| Q4 25 | 103.4% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 76.3% | -90.7% | ||
| Q1 25 | 19.9% | — | ||
| Q4 24 | 273.6% | -721.7% | ||
| Q3 24 | 13.5% | -57.2% | ||
| Q2 24 | -17.5% | — | ||
| Q1 24 | 11.5% | — |
| Q4 25 | $0.44 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $0.14 | $-0.15 | ||
| Q1 25 | $0.03 | — | ||
| Q4 24 | $1.09 | $-0.91 | ||
| Q3 24 | $0.02 | $-0.18 | ||
| Q2 24 | $-0.06 | — | ||
| Q1 24 | $0.01 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $739.2M |
| Total DebtLower is stronger | $161.6M | — |
| Stockholders' EquityBook value | $467.4M | $778.5M |
| Total Assets | $719.1M | $815.1M |
| Debt / EquityLower = less leverage | 0.35× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $739.2M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $834.2M | ||
| Q3 24 | — | $422.7M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $161.6M | — | ||
| Q3 25 | $170.4M | — | ||
| Q2 25 | $193.4M | — | ||
| Q1 25 | $202.6M | — | ||
| Q4 24 | $204.6M | — | ||
| Q3 24 | $394.0M | — | ||
| Q2 24 | $393.0M | — | ||
| Q1 24 | $383.0M | — |
| Q4 25 | $467.4M | — | ||
| Q3 25 | $457.3M | — | ||
| Q2 25 | $473.5M | $778.5M | ||
| Q1 25 | $492.2M | — | ||
| Q4 24 | $494.6M | $757.5M | ||
| Q3 24 | $519.4M | $378.9M | ||
| Q2 24 | $521.5M | — | ||
| Q1 24 | $526.7M | — |
| Q4 25 | $719.1M | — | ||
| Q3 25 | $738.5M | — | ||
| Q2 25 | $776.7M | $815.1M | ||
| Q1 25 | $810.5M | — | ||
| Q4 24 | $869.6M | $864.6M | ||
| Q3 24 | $1.0B | $439.2M | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | 0.35× | — | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.41× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 0.75× | — | ||
| Q1 24 | 0.73× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.4M | $-37.7M |
| Free Cash FlowOCF − Capex | — | $-37.8M |
| FCF MarginFCF / Revenue | — | -197.2% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | 0.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.4M | — | ||
| Q3 25 | $-2.0M | — | ||
| Q2 25 | $-2.2M | $-37.7M | ||
| Q1 25 | $6.4M | — | ||
| Q4 24 | $16.1M | $-37.5M | ||
| Q3 24 | $-4.3M | $-12.5M | ||
| Q2 24 | $-6.1M | — | ||
| Q1 24 | $11.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-37.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -197.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.81× | — | ||
| Q3 25 | -4.04× | — | ||
| Q2 25 | -0.29× | — | ||
| Q1 25 | 3.12× | — | ||
| Q4 24 | 0.27× | — | ||
| Q3 24 | -2.39× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 8.66× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
